Polarean Imaging PLC is a leading medical technology company with a strong emphasis on innovation and excellence. The company is committed to improving the diagnosis and treatment of respiratory diseases through its advanced portfolio of hyperpolarized magnetic resonance imaging (MRI) solutions. Polarean Imaging PLC aims to provide accurate and precise imaging techniques that enable healthcare professionals to make informed decisions and provide the best possible care to patients. With a focus on research and development, Polarean Imaging PLC strives to constantly push the boundaries of medical imaging technology, ensuring a brighter and healthier future for individuals worldwide.

Polarean Imaging PLC is primarily present in the United Kingdom and the United States.

Polarean Imaging PLC has achieved several significant milestones throughout its history. One notable milestone is the successful development and commercialization of its proprietary hyperpolarized gas technology. This groundbreaking technology enables the production of hyperpolarized xenon and helium gases, used in innovative MRI imaging techniques. Additionally, Polarean Imaging PLC has received regulatory approvals for its products, including the Drug Master File from the U.S. FDA. The company has also formed strategic partnerships with leading medical institutions and organizations globally, further enhancing its market presence. These achievements demonstrate Polarean Imaging PLC's commitment to advancing medical imaging solutions and cementing its position as a key player in the industry.

Polarean Imaging PLC, founded in 2009, is a leading medical technology company focused on the development and commercialization of novel drug-device combination products. The company specializes in the production of hyperpolarized xenon gas (129Xe), a unique imaging agent used in magnetic resonance imaging (MRI) to enhance image quality and provide insights into various pulmonary disorders. Polarean Imaging PLC's proprietary technologies and expertise in hyperpolarized gas allow for improved diagnosis and monitoring of respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis. With a strong commitment to advancing respiratory healthcare, Polarean Imaging PLC is revolutionizing patient care through innovative imaging solutions.

The main competitors of Polarean Imaging PLC in the market include companies such as General Electric Company (GE), Siemens Healthineers AG, and Fonar Corporation.

Polarean Imaging PLC is primarily active in the healthcare and medical imaging industries.

The business model of Polarean Imaging PLC revolves around the development and commercialization of advanced medical imaging technology. As a leading company in the field of hyperpolarized gas MRI, Polarean Imaging PLC focuses on enhancing the quality and accuracy of pulmonary imaging. By leveraging its proprietary technology, the company aims to provide healthcare professionals with tools to improve the diagnosis and management of respiratory conditions such as chronic obstructive pulmonary disease (COPD) and lung cancer. Polarean Imaging PLC's innovative approach enables non-invasive and precise assessment of lung function, offering valuable insights for personalized treatment decisions and clinical research.

Polarean Imaging P/E-luku on −0,25.

Polarean Imaging KUV on 2,56.

AlleAktien Laatuscore Polarean Imaging on 2/10.

odotettu Polarean Imaging liikevaihto on 2,02 milj. USD.

odotettu Polarean Imaging voitto on −20,75 milj. USD.

Polarean Imaging PLC is an emerging company in the medical technology industry that specializes in the manufacturing of medical imaging solutions. The company is headquartered in the UK and is listed on the AIM market of the London Stock Exchange. Polarean Imaging's business model is based on the production and sale of hyperpolarization systems, which allow radiologists to obtain more accurate images of the internal organs of the human body. With this technology, doctors can now create real-time images that help detect diseases early and improve treatment options. Polarean's main product is a hyperpolarization system called Polarcath, which measures the oxygen supply to the heart. This system is the first approved method for measuring oxygen supply in patients with cardiovascular diseases. However, Polarean also plans to develop additional hyperpolarization systems to measure other parameters and other diagnostic systems. Polarean has three main business areas: clinical care, research and development, and sales and marketing. In the clinical care field, Polarean collaborates with leading hospitals and medical centers in the UK and Europe to introduce its hyperpolarization systems into practice. The systems are used in clinics to perform pre-treatment examinations and evaluate the effectiveness of treatments. In addition, the company works closely with medical societies to further develop the technology and standardize existing procedures. Polarean's research and development department is actively working on the development of new technologies to improve medical imaging. The company invests several million annually in research to improve the performance of its systems and develop new applications. The focus is on advancing hyperpolarization technology to produce cost- and time-efficient systems. Polarean's sales and marketing department is responsible for the sales and marketing of the hyperpolarization systems. Customer contact is a primary focus. The company has a wide network of distribution partners and sales personnel worldwide, who drive the dissemination of the technology. In conclusion, Polarean Imaging PLC is an innovative company that aims to improve the diagnosis and treatment of diseases through the introduction of new technologies in medical imaging. The company takes a holistic approach that spans from research and development to marketing and clinical care. With extensive investments in research and development, a strong market position, and close collaboration with leading hospitals, Polarean Imaging will establish itself as one of the key players in the medical technology industry.

Polarean Imaging maksaa osinkoa 0 USD, joka jaetaan erässä vuoden aikana.

Osinkoa ei voida tällä hetkellä laskea Polarean Imaging:lle tai yhtiö ei maksa osinkoa.

Polarean Imaging:n ISIN on GB00BF3DT583.

Polarean Imaging:n WKN on A2JHGR.

Polarean Imaging:n tunnus on POLX.L.

Viimeisen 12 kuukauden aikana Polarean Imaging maksoi osinkoa edestä. Tämä vastaa noin osinkotuottoa. Seuraavan 12 kuukauden aikana Polarean Imaging maksanee ennusteiden mukaan 0 USD osingon.

Polarean Imaging:n tämänhetkinen osinkotuotto on .

Polarean Imaging maksaa osinkoa neljännesvuosittain. Osingot jaetaan kuukausina .

Polarean Imaging maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Seuraavalle 12 kuukaudelle odotetaan 0 USD suuruisia osinkoja. Tämä vastaa 0 % osinkotuottoa.

Polarean Imaging kuuluu sektoriin 'Terveys'.

Saadaksesi viimeisimmän Polarean Imaging osingon 10.7.2024, jonka suuruus on 0 USD, sinun oli oltava omistanut osakkeen ennen ex-päivää, joka oli 10.7.2024.

Viimeisin osinko maksettiin 10.7.2024.

Vuonna 2023 Polarean Imaging maksoi 0 USD osinkoina.

Polarean Imaging:n osingot maksetaan USDssa.